:EGFRNSCLC,

Ken Akao1, Yuko Oya1, Takaya Sato1

  • 1Department of Respiratory Medicine, School of medicine, Fujita Health University, Toyoake 470-1192, Japan.

概括

免疫检查点抑制剂 (ICI) 在EGFR突变非小细胞肺癌 (NSCLC) 中具有有限的疗效. 本综述探讨了ICI在TKI耐药NSCLC中的潜力,重点关注克服治疗挑战.

相关概念视频

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K